Marked improvement of overall survival in mantle cell lymphoma: A population based study from the Swedish Lymphoma Registry

Leukemia and Lymphoma

Volumn 52, Issue 10, 2011, Pages 1929-1935

  Abrahamsson, Anna ^a   Dahle, Nina ^a   Jerkeman, Mats ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Mantle cell lymphoma; population; Swedish Lymphoma Registry

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; NIGHT SWEAT; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; SWEDEN; SYMPTOM;

COHORT STUDIES; HUMANS; LYMPHOMA, MANTLE-CELL; MULTIVARIATE ANALYSIS; PROGNOSIS; REGISTRIES; SURVIVAL RATE; SWEDEN;

EID: 80053189765     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.587560     Document Type: Article

References (9)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-2795. (Pubitemid 28363044)
2. van de Schans SA, Janssen-Heijnen ML, Nijziel MR, Steyerberg EW, van Spronsen DJ. Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting. Haematologica 2010;95:1503-1509.
3. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-197. (Pubitemid 37443390)
4. Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood 2010;116(Suppl. 1): Abstract 110.
5. Lenz G, DreylingM, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984-1992. (Pubitemid 46211378)
6. Dreyling M, Lenz G, Hoster E, et al. Early consolidation byn myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677-2684. (Pubitemid 40450320)
7. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression- free survival of mantle cell lymphoma after intensive frontline immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-2693.
8. Rummel M, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as firstline treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009;114(Suppl. 1): Abstract 405.
9. Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008;113:791-798.